To evaluate the role of bevacizumab injected into the silicone oil at the end of retinal reattachment surgery for rhegmatogenous retinal detachment (RRD) associated with severe proliferative ...

EYLEA Now Approved for Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Macular Edema following RVO TARRYTOWN, N.Y., Oct. 6, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals ...

Impressive new work from an international team of scientists has demonstrated a potential way to restore vision in those suffering from degenerative diseases of the retina. A single injection of ...

An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...

Please provide your email address to receive an email when new articles are posted on . Anti-VEGF injections can help maintain and sometimes improve visual acuity in patients with degenerative retinal ...

Santen Pharmaceutical has signed a licensing agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein designed to treat retinal diseases. The agreement, facilitated ...

TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...

Please provide your email address to receive an email when new articles are posted on . VANCOUVER, British Columbia — A single subconjunctival 4 mg triamcinolone injection after retinal surgery had ...

TARRYTOWN, N.Y., June 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for ...

Surgeons have operated on a patient with retinal vein occlusion using a surgical robot. Operated by an eye surgeon, the robot uses a needle of barely 0.03 millimeter to inject a thrombolytic drug into ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron ...